GAMEXP
"Genomic approaches to metabolite exploitation from Xenorhabdus, Photorhabdus"
| Coordinatore | JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.gamexp.eu/ |
| Totale costo | 3˙403˙680 € |
| EC contributo | 2˙689˙160 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-SICA |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-03-01 - 2012-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | coordinator | 700˙400.00 |
| 2 |
THE UNIVERSITY OF EXETER
Organization address
address: Northcote House, The Queen's Drive contact info |
UK (EXETER) | participant | 682˙200.00 |
| 3 |
UNIVERSITY OF BATH
Organization address
address: CLAVERTON DOWN contact info |
UK (BATH) | participant | 656˙400.00 |
| 4 |
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Organization address
address: Science Park 1, Stuhlsatzenhausweg 69 contact info |
DE (SAARBRUECKEN) | participant | 395˙200.00 |
| 5 |
MAHIDOL UNIVERSITY
Organization address
address: RATCHAWITHI ROAD 420/6 contact info |
TH (BANGKOK) | participant | 139˙760.00 |
| 6 |
INSTITUTE OF ECOLOGY AND BIOLOGICAL RESOURCES VIETNAMESE ACADEMY OF SCIENCE AND TECHNOLOGY
Organization address
address: "HOANG QUOC VIET, NGHIADO 18" contact info |
VN (HANOI) | participant | 115˙200.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The majority of compounds used to treat diseases come from a single group of organisms, the actinomycetes. This over-reliance on a single organism to produce the worlds drugs is a major problem for the development of compounds with alternative modes of action which can overcome and delay the onset of drug resistance. To address this problem we will form an international multi-disciplinary group of experts to bioprospect for biologically active natural products. The central aim of this programme is to start rapidly deriving novel drugs from non-actinomycete sources. We will isolate novel strains of the proven but not well-explored drug producers Xenorhabdus and Photorhabdus. These bacteria will be isolated from insect pathogenic nematodes and characterized taxonomically (WP1) and strains will be analyzed for the production of novel compounds (WP2). This library of compounds will then be tested against a broad set of targets including bacteria, fungi, protozoans, nematodes, insects, and mammalian cell cultures (WP3). The five most productive bacterial strains will then be fully sequenced and used to construct genomic libraries. These libraries will be used to generate recombinant clones in heterologous hosts, enabling fast and efficient biotechnological production of the bioactive compounds (WP4). To ensure efficient interactions and comparability of results, especially regarding the bioactivity data, training sessions will be organized with seminars and hands on experience for each of the groups at a central site (WP5). Robust patent stuctures will ensure efficient technology transfer to our industrial partners (WP6) and overall coordination of the scientific and training programs will be overseen by WP7.'
Introduzione (Teaser)
EU-funded scientists have characterised bioactive compounds produced by novel strains of bacteria. Commercial production could combat the life-threatening drug resistance of many infectious diseases.